Amgen Shrugs Off Turkish Price Cuts, Snatches Up Mustafa Nevzat For Broader Reach Into Emerging Markets
This article was originally published in PharmAsia News
Executive Summary
Despite harsh price cuts in Turkey that have taken a toll on multinationals, Amgen dives head first into the market.
You may also be interested in...
Amgen Hits Another Emerging Market Target With $700M Turkish Deal
Fulfilling its pledge to dramatically expand internationally, Amgen sealed a deal to purchase coveted drugmaker Mustafa Nevzat, gaining a foothold in Turkey. Meanwhile, its pipeline progresses with no clear winners to help cushion the blows to the company’s ESAs.
With December Approaching, Are More Turkish Price Cuts On The Way?
Turkey has attracted considerable attention in recent years from multinational pharmaceutical companies looking to grow in emerging markets. But the government of the world's 12-largest pharmaceutical market has also enforced steep price cuts on drugs in each of the last two years, both times in December. With December quickly approaching, are a new round of price cuts on the horizon
Lilly Among MNCs Scouting In Turkey For Local Partners As GMP Inspection Backlog Continues
Eli Lilly & Co. Inc. has been rumored to be in partnership talks with Turkish Mustafa Nevzat Pharmaceuticals. The U.S. drug maker is reportedly looking for a minority stake in the Turkish generics maker